Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5875996 | 0.89 | NR1H2 (0.38) | NR1H2NR1H3GAACYP2C19MEN1 | |
| SCHEMBL5877382 | 0.89 | GBA1 (0.34) | GBA1NR1H2NR1H3GAAMEN1 | |
| SCHEMBL5877823 | 0.87 | NR1H2 (0.33) | NR1H2NR1H3GAACYP2C19MEN1 | |
| SCHEMBL5876077 | 0.87 | GBA1 (0.33) | GBA1NR1H2NR1H3 | |
| SCHEMBL5876902 | 0.87 | NR1H2 (0.33) | NR1H2NR1H3GAACYP2C19MEN1 | |
| SCHEMBL5876863 | 0.86 | GBA1 (0.36) | GBA1NR1H2NR1H3GAACYP2C19 | |
| SCHEMBL5877420 | 0.85 | NR1H2 (0.32) | NR1H2NR1H3GAACYP2C19MEN1 | |
| SCHEMBL5877755 | 0.85 | GBA1 (0.35) | GBA1NR1H2NR1H3GAACYP2C19 | |
| SCHEMBL5876451 | 0.85 | NR1H2 (0.34) | NR1H2NR1H3GAACYP2C19MEN1 | |
| SCHEMBL5877764 | 0.85 | NR1H2 (0.35) | GBA1NR1H2NR1H3GAACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119115-B2 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | IDO1, IDO2, INMT | GBA1 2736/4885NR1H2 556/4885NR1H3 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.